Currently out of the existing stock ratings of Sumant Kulkarni, 137 are a BUY (86.16%), 22 are a HOLD (13.84%).

Sumant Kulkarni

Work Performance Price Targets & Ratings Chart

Analyst Sumant Kulkarni, currently employed at CANACCORD, carries an average stock price target met ratio of 39.35% that have a potential upside of 29.99% achieved within 176 days.

Sumant Kulkarni’s has documented 315 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CMPS, Compass Pathways Plc at 28-Feb-2025.

Wall Street Analyst Sumant Kulkarni

Analyst best performing recommendations are on CRTX (CORTEXYME).
The best stock recommendation documented was for CRTX (CORTEXYME) at 6/3/2019. The price target of $42 was fulfilled within 15 days with a profit of $17.87 (74.06%) receiving and performance score of 49.37.

Average potential price target upside

ACAD ACADIA Pharmaceuticals ATAI ATAI Life Sciences BV BHVN Biohaven Pharmaceutical Holding Co Ltd BIIB Biogen BTAI BioXcel Therapeutics CRTX Cortexyme ITCI Intracellular Th NBIX Neurocrine Biosciences SAGE Sage Therapeutic VYGR Voyager Therapeutics ZYNE Zynerba Pharmaceuticals CARA Cara Therapeutic CMPS Compass Pathways Plc CYBN Cybin  KMPH KemPharm TEVA Teva Pharma Industries Ltd ADR ALDR Alder BioPharmaceuticals CLNN Clene ANVS Annovis Bio  GHRS GH Research PLC MNMD Mind Medicine  STOK Stoke Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$28

$8.4 (42.86%)

$28

4 days ago
(27-Feb-2025)

25/37 (67.57%)

$8.66 (44.78%)

486

Buy

$27

$7.4 (37.76%)

$27

4 days ago
(27-Feb-2025)

7/21 (33.33%)

$7.66 (39.61%)

118

Buy

$28

$8.4 (42.86%)

$28

4 days ago
(27-Feb-2025)

0/6 (0%)

$8.66 (44.78%)

Hold

$22

$2.4 (12.24%)

$24

20 days ago
(11-Feb-2025)

16/21 (76.19%)

$3.51 (18.98%)

174

Hold

$20

$0.4 (2.04%)

$25

2 months ago
(03-Jan-2025)

5/6 (83.33%)

$1.59 (8.64%)

172

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Sumant Kulkarni is most bullish on?

Potential upside of $63.47 has been obtained for CYBN (CYBIN )

Which stock is Sumant Kulkarni is most reserved on?

Potential downside of -$0 has been obtained for ATAI (ATAI LIFE SCIENCES BV)

What Year was the first public recommendation made by Sumant Kulkarni?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?